Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. Needham & Company LLC’s target price would suggest a potential upside of 172.37% from the stock’s previous close.

Several other research analysts have also recently issued reports on TSHA. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Chardan Capital increased their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st. Canaccord Genuity Group reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Finally, Piper Sandler began coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $6.88.

Taysha Gene Therapies Trading Up 6.2 %

NASDAQ:TSHA traded up $0.15 on Thursday, reaching $2.57. The company’s stock had a trading volume of 1,065,447 shares, compared to its average volume of 2,514,342. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. The firm has a market cap of $480.64 million, a price-to-earnings ratio of -3.84 and a beta of 0.37. The stock has a 50 day moving average price of $2.65 and a 200 day moving average price of $2.09.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The firm had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $4.75 million. On average, equities analysts anticipate that Taysha Gene Therapies will post -0.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently bought and sold shares of TSHA. Howard Capital Management Inc. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $25,000. Victory Capital Management Inc. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $28,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $31,000. Lee Financial Co purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter worth $63,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Taysha Gene Therapies in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.